Status:

COMPLETED

Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)

Lead Sponsor:

Yonsei University

Conditions:

MV(Mitral Valve) Repair

Eligibility:

All Genders

20-85 years

Phase:

PHASE3

Brief Summary

1. objectives: The primary aim of ENAVLE is to explore the efficacy of edoxaban in patients with post mitral valve repair or bioprosthetic valve implantation 2. Primary / Secondary Endpoint 1\) Effic...

Detailed Description

This study is an open labeled, parallel group, and randomization study. At 7 days after mitral valve repair, bioprosthetic MV or AV replacement surgery, warfarin or edoxaban will be started per oral r...

Eligibility Criteria

Inclusion

  • Patients aged 20-85 years with
  • MV repair or Bioprosthetic MV or AV replacement
  • Patients with written informed consent

Exclusion

  • Previous mechanical prosthetic heart valve replacement
  • Patients who underwent TAVI
  • Concomitant bioprosthetic valve replacement of mechanical tricuspid or pulmonary replacement at the time of the index valve replacement surgery
  • Clinically relevant paravalvular leaks
  • Previous history of endocarditis
  • Complex congenital heart abnormality
  • Acute coronary syndrome within one month
  • Uncontrolled hypertension
  • Previous history of hemorrhagic stroke
  • At high risk for bleeding
  • Active hepatitis or liver dysfunction (AST/ALT\> 3times of upper normal limits)
  • Creatinine clearance \< 30ml/min
  • Patients with a clear indication for long-term dual antiplatelet therapy
  • Malignancy or radiation therapy within one month
  • Treatment with selected drugs that my interact with edoxaban (specific P-gp inhibitors, ie. verapamil, quinidine; the short-term use of azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole)
  • At of pregnancy or breastfeeding
  • Known allergy to warfarin or edoxaban

Key Trial Info

Start Date :

December 1 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2019

Estimated Enrollment :

220 Patients enrolled

Trial Details

Trial ID

NCT03244319

Start Date

December 1 2017

End Date

September 30 2019

Last Update

January 2 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine

Seoul, South Korea, 03722

Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial) | DecenTrialz